menu
    • menu
    [{"orgOrder":0,"company":"RemeGen","sponsor":"Lilly Asia Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Large molecule","year":"2020","type":"Financing","leadProduct":"Telitacicept","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"RemeGen \/ Lilly Asia Ventures","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Lilly Asia Ventures"},{"orgOrder":0,"company":"RemeGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"CHINA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Telitacicept","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"RemeGen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RemeGen \/ Not Applicable"},{"orgOrder":0,"company":"RemeGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Disitamab vedotin","moa":"HER2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"RemeGen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RemeGen \/ Not Applicable"},{"orgOrder":0,"company":"RemeGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Disitamab vedotin","moa":"HER2 receptor","graph1":"Oncology","graph2":"Approved","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"RemeGen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"RemeGen \/ Not Applicable"},{"orgOrder":0,"company":"RemeGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Disitamab vedotin","moa":"HER2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"RemeGen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RemeGen \/ Not Applicable"},{"orgOrder":0,"company":"RemeGen","sponsor":"Seagen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Disitamab Vedotin","moa":"HER2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"RemeGen","amount2":2.6000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":2.6000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"RemeGen \/ Seagen","highestDevelopmentStatusID":"8","companyTruncated":"RemeGen \/ Seagen"},{"orgOrder":0,"company":"RemeGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Disitamab Vedotin","moa":"HER2 receptor","graph1":"Oncology","graph2":"Approved","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"RemeGen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"RemeGen \/ Not Applicable"},{"orgOrder":0,"company":"RemeGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Interleukin-2","moa":"TNF-13","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"RemeGen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Not Applicable"},{"orgOrder":0,"company":"RemeGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Telitacicept","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"RemeGen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RemeGen \/ Not Applicable"},{"orgOrder":0,"company":"RemeGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"RC118","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"RemeGen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"RemeGen \/ Not Applicable"},{"orgOrder":0,"company":"RemeGen","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"RC88","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"RemeGen \/ Innovent Biologics","highestDevelopmentStatusID":"7","companyTruncated":"RemeGen \/ Innovent Biologics"},{"orgOrder":0,"company":"RemeGen","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"RC88","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"RemeGen \/ Innovent Biologics","highestDevelopmentStatusID":"7","companyTruncated":"RemeGen \/ Innovent Biologics"},{"orgOrder":0,"company":"RemeGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"RC88","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RemeGen \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"RemeGen \/ Not Applicable"},{"orgOrder":0,"company":"RemeGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Telitacicept","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"RemeGen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Not Applicable"},{"orgOrder":0,"company":"RemeGen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Telitacicept","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"RemeGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"RemeGen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"RemeGen \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by RemeGen

    Menu

    RemeGen

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            RemeGen

                            China arrow
                            American Pharma Summit
                            Not Confirmed

                            RemeGen

                            China arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telitacicept

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            RemeGen Completes Enrollment in Phase III Trials of Telitacicept for IgA Nephropathy

                            Details : RC18 (telitacicept) targets BLyS and a proliferation inducing ligand, which allows it to effectively reduce B-cell mediated autoimmune responses that are implicated in autoimmune diseases like IgAN.

                            Brand Name : RC18

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 21, 2024

                            Lead Product(s) : Telitacicept

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            RemeGen

                            China arrow
                            American Pharma Summit
                            Not Confirmed

                            RemeGen

                            China arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telitacicept

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            RemeGen's Telitacicept Granted Fast Track Designation for Primary Sjögren's Syndrome

                            Details : RC18 (telitacicept) targets BLyS and APRIL, two critical molecules for B-cell development, effectively reducing autoimmune responses in several autoimmune diseases by modulating B-cell activity.

                            Brand Name : RC18

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 02, 2024

                            Lead Product(s) : Telitacicept

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            RemeGen

                            China arrow
                            American Pharma Summit
                            Not Confirmed

                            RemeGen

                            China arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RC88

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            RemeGen's RC88 Obtains FDA Fast Track Designation for Ovarian Cancer Treatment

                            Details : RC88 is a mesothelin-targeting ADC in phase 2 trials for treating platinum-resistant recurrent ovarian, fallopian tube, and primary peritoneal cancers.

                            Brand Name : RC88

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 12, 2024

                            Lead Product(s) : RC88

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            RemeGen

                            China arrow
                            American Pharma Summit
                            Not Confirmed

                            RemeGen

                            China arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RC88,Sintilimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Innovent Biologics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            RemeGen and Innovent Collaborate on Clinical Trials to Evaluate the Potential of RC88 and RC108 Combined with ...

                            Details : The collaboration will focus on conducting clinical trials exploring combination therapies of the novel antibody-drug conjugates, RC88 (targeting MSLN) and RC108 (targeting c-MET), along with the PD-1 inhibitor sintilimab injection (TYVYT®).

                            Brand Name : RC88

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 09, 2023

                            Lead Product(s) : RC88,Sintilimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Innovent Biologics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            RemeGen

                            China arrow
                            American Pharma Summit
                            Not Confirmed

                            RemeGen

                            China arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RC88,Sintilimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Innovent Biologics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Innovent and RemeGen Enter into Clinical Trial Collaboration Investigating Combination Therapy of TYVYT® (sin...

                            Details : Under the agreement, Innovent will provide supplies of TYVYT® (sintilimab injection) and RemeGen will conduct Phase 1/2a studies to evaluate the anti-tumor activity of the combination therapy of TYVYT® with RC88 or RC108 in Chinese patients with advanc...

                            Brand Name : RC88

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 25, 2023

                            Lead Product(s) : RC88,Sintilimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Innovent Biologics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            RemeGen

                            China arrow
                            American Pharma Summit
                            Not Confirmed

                            RemeGen

                            China arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RC118

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            RemeGen's RC118 for Injection Targeting Claudin 18.2 in Patients with Gastric and Pancreatic Cancers Granted T...

                            Details : RC118 is RemeGen's latest advanced antibody-drug conjugate used to treat patients with solid tumors positive for Claudin 18.2 expressions. ADC product pipeline, with no less than four products, including the latest RC118, entering clinical trials or gain...

                            Brand Name : RC118

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 12, 2022

                            Lead Product(s) : RC118

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            RemeGen

                            China arrow
                            American Pharma Summit
                            Not Confirmed

                            RemeGen

                            China arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telitacicept

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            RemeGen Releases Phase II Clinical Study Data for Treatment of Myasthenia Gravis in Chinese Patients

                            Details : RC18 (telitacicept) targets two cell-signaling molecules critical for B-lymphocyte development: BLyS and a proliferation inducing ligand, which allows it to effectively reduce B-cell mediated autoimmune responses that are implicated in several autoimmune...

                            Brand Name : RC18

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 01, 2022

                            Lead Product(s) : Telitacicept

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            RemeGen

                            China arrow
                            American Pharma Summit
                            Not Confirmed

                            RemeGen

                            China arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Telitacicept,Interleukin 2

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            RemeGen Announces Preliminary Results of Phase III Confirmatory Study of Telitacicept for Treatment of Systemi...

                            Details : Preliminary results from the full analysis set (FAS) showed that at week 52, patients who received RC-18 (telitacicept) had a significantly higher rate of SRI-4 (The Systemic Lupus Erythematosus Responder Index 4) response than those who received placebo...

                            Brand Name : RC-18

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 19, 2022

                            Lead Product(s) : Telitacicept,Interleukin 2

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            RemeGen

                            China arrow
                            American Pharma Summit
                            Not Confirmed

                            RemeGen

                            China arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Disitamab Vedotin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Seagen

                            Deal Size : $2,600.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Seagen and RemeGen Announce Exclusive Worldwide License and Co-Development Agreement for Disitamab Vedotin

                            Details : Seagen Licenses Disitamab Vedotin, a Novel HER2-targeted Antibody-Drug Conjugate (ADC) from RemeGen. Disitamab vedotin is a novel ADC that selectively delivers the anti-cancer agent monomethyl auristatin E (MMAE) into HER2-expressing tumor cells.

                            Brand Name : RC48

                            Molecule Type : Large molecule

                            Upfront Cash : $200.0 million

                            August 09, 2021

                            Lead Product(s) : Disitamab Vedotin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Seagen

                            Deal Size : $2,600.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            RemeGen

                            China arrow
                            American Pharma Summit
                            Not Confirmed

                            RemeGen

                            China arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Disitamab Vedotin

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Disitamab Vedotin Has Become the First Adc Drug Created and Developed by A China Biopharma to Receive Marketin...

                            Details : The approval of Disitamab vedotin has broken the situation that there is no original domestic new drug in the field of ADC drugs, and filled the gap in the global post-line treatment of patients with HER2 over-expression of gastric cancer.

                            Brand Name : Aidexi

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 09, 2021

                            Lead Product(s) : Disitamab Vedotin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth